Trial Profile
Neuroprotective effect of Fingolimod in patients with Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2019
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 12 Nov 2019 Results assess whether fingolimod induces secretion of neurotrophins by immune cellspublished in the CNS Drugs
- 29 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis